Medivir AB (FRA:MVR0)
€ 0.211 -0.017 (-7.46%) Market Cap: 27.91 Mil Enterprise Value: 14.54 Mil PE Ratio: 0 PB Ratio: 1.77 GF Score: 46/100

Q1 2023 Medivir AB Earnings Call Transcript

Apr 27, 2023 / 01:00PM GMT
Release Date Price: €0.535828 (+0.32%)
Jens Lindberg
Medivir AB - CEO

Thank you, and welcome, everyone, to the Medivir quarter-one webcast. Let's move forward. I will be taking most of the presentation. But in the room with me when we move into the question-and-answer sessions is our CFO, Magnus Christensen. And I'm also joined by our recently joined CMO, Pia Baumann; and our CSO, Fredrik Ãberg. So with that, let's move into the events of quarter one.

Important information -- as always, you'll find the presentation on our website, and you can have a look at the information there. Quarter one has been a very good quarter, from a Medivir perspective, both with regards to our main in-house project, fostrox, and our pipeline projects.

And if we look at the fostrox development at the first go, we've seen that development picked up speed quite nicely in the first quarter. We were able to establish the recommended Phase II dose for the first combination arm, which was for fostrox and Lenvima, where we were able to dose up to 30 milligram.

In addition, we were able to very quickly turn that around as we moved into Phase

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot